Toronto, ON | Barcelona, Spain – Altis Labs, Inc. (“Altis”) is announcing results presented at this year’s European Society of Medical Oncology conference: IPRO provides better prognostication of overall survival compared to TNM stage in patients with aNSCLC.  

IPRO is a fully-automated deep learning system developed by Altis. Using a real-world dataset curated in collaboration with the University of Calgary, IPRO processed pre-treatment CT scans of stage IIIB and IV NSCLC patients to generate prognostic predictions beyond tumor, node, metastasis (TNM) sub-stages.

According to IPRO, the 33% of patients predicted to have the highest mortality risk had significantly lower median survival (2.7 months vs. 7.5 months) compared to the 33% of patients predicted to have the lowest risk. IPRO provides higher discrimination of overall survival compared to TNM staging in aNSCLC patients.

This work highlights that IPRO may provide greater utility than staging as a prognostic factor in future clinical research, and may also have greater utility in determining clinical trial eligibility and/or stratification. 

Dr. Omar F. Khan, a medical oncologist from Tom Baker Cancer Center, University of Calgary, was the lead author of the study.

Read the full abstract here.

‍

About Altis Labs

Altis Labs is the computational imaging company accelerating clinical trials with AI. 

Altis has created the industry's largest real-world Imaging, Clinical, and Outcomes database – comprising over 210 million cancer patient images linked to associated demographic, diagnostic, molecular, treatment, and survival information. Deep learning models trained on rwICO can generate profound insights beyond tumor measurements that make up reductionist criteria like RECIST 1.1, yielding greater association with overall survival. 

Top 20 biopharma sponsors apply our deep learning models to their clinical trial imaging data to unlock powerful insights. Our models instantaneously generate Imaging-based Prognostication (IPRO) scores and thousands of Spatial Imaging Biomarkers (SIBs) from each scan, which Sponsors can combine for analysis with other data modalities such as ctDNA. These insights are being explored by clinical development teams to quantify treatment effects earlier in order to design more successful clinical trials. 

Our multi-disciplinary team is on a mission to help get the most effective novel treatments to patients sooner. Altis is proudly headquartered in Toronto, Canada.

To learn more, email info@altislabs.com.